|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan显示文摘AIM:To evaluate the efficacy of pegylated interferon α-2b(peg-IFNα-2b) plus ribavirin(RBV) therapy in Japanese patients with chronic hepatitis C(CHC) genotype Ib and a high viral load.METHODS:One hundred and twenty CHC patients(58.3% male) who received peg-IFNα-2b plus RBV therapy for 48 wk were enrolled.Sustained virological response(SVR) and clinical parameters were evaluated.RESULTS:One hundred(83.3%) of 120 patients completed 48 wk of treatment.53 patients(44.3%) achieved SVR.Early virological response(EVR) and end of treatment response(ETR) rates were 50% and 73.3%,respectively.The clinical parameters(SVR vs non-SVR) associated with SVR,ALT(108.4 IU/L vs 74.5 IU/L,P = 0.063),EVR(76.4% vs 16.4%,P < 0.0001),adherence to peg-IFN(≥ 80% of planned dose) at week 12(48.1% vs 13.6%,P = 0.00036),adherence to peg-IFN at week 48(54.7% vs 16.2%,P < 0.0001) and adherence to RBV at week 48(56.1% vs 32.1%,P = 0.0102) were determined using univariate analysis,and EVR and adherence to peg-IFN at week 48 were determined using multivariate analysis.In the older patient group(> 56 years),SVR in females was significantly lower than that in males(17% vs 50%,P = 0.0262).EVR and adherence to Peg-IFN were demonstrated to be the main factors associated with SVR.CONCLUSION:Peg-IFNα-2b plus RBV combination therapy demonstrated good tolerability in Japanese patients with CHC and resulted in a SVR rate of 44.3%.Treatment of elderly female patients is still challenging and maintenance of adherence to peg-IFNα-2b is important in improving the SVR rate. | Takayuki Kogure Yoshiyuki Ueno Koji Fukushima Futoshi Nagasaki Yasuteru Kondo Jun Inoue Yasunori Matsuda Eiji Kakazu Takeshi Yamamoto Hiroyoshi Onodera Yutaka Miyazaki Hiromasa Okamoto Takehiro Akahane Tomoo Kobayashi Yutaka Mano Takao Iwasaki Motoyasu Ishii Tooru Shimosegawa | 2008 | World Journal of Gastroenterology2008，14，47： | 7 |
| 2 | Measurement of prostaglandin metabolites is useful in diagnosis of small bowel ulcerations显示文摘BACKGROUND We recently reported on a hereditary enteropathy associated with a gene encoding a prostaglandin transporter and referred to as chronic enteropathy associated with SLCO2 A1 gene(CEAS). Crohn's disease(CD) is a major differential diagnosis of CEAS, because these diseases share some clinical features. Therefore, there is a need to develop a convenient screening test to distinguish CEAS from CD.AIM To examine whether prostaglandin E major urinary metabolites(PGE-MUM) can serve as a biomarker to distinguish CEAS from CD.METHODS This was a transactional study of 20 patients with CEAS and 98 patients with CD.CEAS was diagnosed by the confirmation of homozygous or compound heterozygous mutation of SLCO2 A1. We measured the concentration of PGEMUM in spot urine by radioimmunoassay, and the concentration was compared between the two groups of patients. We also determined the optimal cut-off value of PGE-MUM to distinguish CEAS from CD by receiver operating characteristic(ROC) curve analysis.RESULTS Twenty Japanese patients with CEAS and 98 patients with CD were enrolled.PGE-MUM concentration in patients with CEAS was significantly higher than that in patients with CD(median 102.7 vs 27.9 μg/g × Cre, P < 0.0001). One log unit increase in PGE-MUM contributed to 7.3 increase in the likelihood for the diagnosis of CEAS [95% confidence interval(CI) 3.2-16.7]. A logistic regression analysis revealed that the association was significant even after adjusting confounding factors(adjusted odds ratio 29.6, 95%CI 4.7-185.7). ROC curve analysis revealed the optimal PGE-MUM cut-off value for the distinction of CEAS from CD to be 48.9 μg/g × Cre with 95.0% sensitivity and 79.6% specificity.CONCLUSION PGE-MUM measurement is a convenient, non-invasive and useful test for the distinction of CEAS from CD. | Yuichi Matsuno Junji Umeno Motohiro Esaki Yoichiro Hirakawa Yuta Fuyuno Yasuharu Okamoto Atsushi Hirano Shigeyoshi Yasukawa Fumihito Hirai Toshiyuki Matsui Shuhei Hosomi Kenji Watanabe Naoki Hosoe Haruhiko Ogata Tadakazu Hisamatsu Shunichi Yanai Shuji Kochi Koichi Kurahara Tsuneyoshi Yao Takehiro Torisu Takanari Kitazono Takayuki Matsumoto | 2019 | World Journal of Gastroenterology2019，25，14： | 5 |
| 3 | The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations显示文摘For patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the relationship between the dose or duration of treatment with tyrosine kinase inhibitor (TKI) and overall survival remains unclear. Here, we analyzed clinical data of 39 patients who were diagnosed with EGFR mutation-positive non-small cell lung cancer and treated with TKI, but subsequently died. Several parameters were measured in this study: overall survival; first, second, and overall TKI therapy durations; first TKI intensity (actual dose/normal dose); and TKI rate (overall TKI therapy duration/overall survival). The response rate to TKI therapy was 50% , and the median survival was 553 days. After TKI therapy failed, 38.5% patients were re-challenged with TKI. We observed a moderate relationship [r = 0.534, 95% confidential interval (CI) = 0.263 to 0.727, P < 0.001] between overall TKI therapy duration and overall survival. However, we found no relationship between overall survival and first TKI intensity (r = 0.073, 95% CI = -0.380 to 0.247, P = 0.657) or TKI rate (r = 0.0345, 95% CI = -0.284 to 0.346, P = 0.835). Nonsmall cell lung cancer patients with mutation-positive tumors remained on TKI therapy for, on average, 33% of the overall survival time. These findings suggest that patients with EGFR mutation-positive tumors should not stick to using TKIs. | Hidekazu Suzuki Tomonori Hirashima Norio Okamoto Tadahiro Yamadori Motohiro Tamiya Naoko Morishita Takayuki Shiroyama Tomoyuki Otsuka Kanako Kitai Ichiro Kawase | 2013 | Chinese Journal of Cancer2013，32，3： | 3 |
| 4 | Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models显示文摘 | Osamu Tohyama Junji Matsui Kotaro Kodama Naoko Hata-Sugi Takayuki Kimura Kiyoshi Okamoto Yukinori Minoshima Masao Iwata Yasuhiro Funahashi Giovanni Tallini | 2014 | Journal of Thyroid Research2014，，： | 1 |
| 5 | Toughening mechanism in a ternary polymer alloy: PBT/PC/rubber system显示文摘 | Okamoto Masami Shinoda Yoshihiro Kojima Takayuki | 1993 | Polymer1993，34，23： | 1 |
| 6 | Muscle stiffness sensor to control an assistance device for the disabled显示文摘 | Shunji Moromugi Yasuhiro Koujina Seigo Ariki Akira Okamoto Takayuki Tanaka Maria Q. Feng Takakazu Ishimatsu | 2004 | Artificial Life and Robotics2004，，1： | 1 |
| 7 | Fourier transform spectrometer with a self-scanning photodiode array 显示文摘 | Takayuki Okamoto Satoshi Kawata Shigeo Minami | 1984 | Applied Optics1984，23，2： | 1 |
| 8 | The targeting of anionized polyvinylpyrrolidone to the renal system显示文摘 | Hiroshi Kodaira Yasuo Tsutsumi Yasuo Yoshioka Haruhiko Kamada Yoshihisa Kaneda Yoko Yamamoto Shin-ichi Tsunoda Takayuki Okamoto Yohei Mukai Hiroko Shibata Shinsaku Nakagawa Tadanori Mayumi | 2003 | Biomaterials2003，，18： | 1 |
| 9 | Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations显示文摘 | Akihiro Tamiya Motohiro Tamiya Takayuki Shiroyama Nobuhiko Saijo Takeshi Nakatani Shojiro Minomo Taisuke Tsuji Naoko Takeuchi Naoki Omachi Kanako Kurata Hidekazu. Suzuki Norio Okamoto Kyoichi Okishio Tomonori Hirashima Shinji Atagi | 2015 | Medical Oncology2015，，3： | 1 |
| 10 | Preparation of rare-earth-metal oxalate spherical particles in emulsion liquid membrane system using alkylphosphinic acid as cation carrier显示文摘 | Takayuki Hirai Norihiko Okamoto Isao Komasawa | 1998 | Langmuir1998，14，： | 1 |
| 11 | Inhibitory effects of tert‐butylhydroquinone on osteoclast differentiation via up‐regulation of heme oxygenase‐1 and down‐regulation of HMGB1 release and NFATc1 expression显示文摘 | Yu Yamaguchi Eiko Sakai Hiroshi Sakamoto Reiko Fumimoto Yutaka Fukuma Kazuhisa Nishishita Kuniaki Okamoto Takayuki Tsukuba | 2014 | J. Appl. Toxicol2014，，： | 1 |
| 12 | Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease显示文摘The pathologies associated with age-related brain dysfunction,including Alzheimer's disease(AD),Parkinson's disease,Lewy body dementia,and vascular dementia,often share similarities across multiple diseases.1 While various factors,such as amyloidβ,Tau protein,α-synuclein,chronic inflammation,and impaired cerebral microcirculation have been suggested as potential therapeutic targets,addressing a single factor is unlikely to be sufficient in preventing or treating age-related brain dysfunction.Drawing from these observations. | Akihiko Taguchi Yuka Okinaka Akiko Takeda Takayuki Okamoto Johannes Boltze Carsten Claussen Sheraz Gul | 2023 | Neuroprotection2023，1，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员